Table 1.

Characteristics of study participantsa

Subject codeAge (yr)HandednessSexETDRSMoCADisease duration (yr)Hoehn-Yahr stage (0-5)bUPDRS score (0-132)cDominant arm rigidity (0-4)Test orderCombination levodopa (mg)d
P2367RHM20/40-22732442NA0
P2478RHF20/25-12762441OFF/ON750
P2684RHM20/25-124142493ON/OFF2250
P2971RHM20/202782483ON/OFF1625
P3061RHF20/16-2309.52351ON/OFF812.5
P3167RHM20/16-2270.52343ON/OFF687.5
P3261RHM20/16-12882402OFF/ON2000
P3465RHM20/25-12742141ON/OFF1000
P3578RHF20/50-227162392ON1625
P3667RHM20/20-126102150OFF/ON1000
P3765RHM20/25-128202292OFF/ON750
P3858RHF20/2027253542ON1000
P4372RHM20/25-22852182OFF/ON1187.5
P4458RHM20/20-13042362ON/OFF937.5
P4541RHF20/12.5-13032212OFF/ON800
P4970RHM20/20-12613280ON1875
Mean ± SD66.4 ± 9.920/22-1 ± 0.227.4 ± 1.69.71 ± 7.02.1 ± 0.333 ± 13.91.75 ± 0.91143.8 ± 584.0
C2574RHM20/25-126
C2781RHF20/16-228
C2860RHM20/32-125
C3968LHF20/20-128
C4064RHF20/20-130
C4161LHM20/2527
C4269RHM20/16-129
C4662RHM20/16-229
C4761RHMmissing29
C4874LHM20/12.5-228
C5069RHF20/20-126
C5178RHM20/20-226
C5271RHM20/25-128
C5369RHM20/16-129
C5479RHM20/2030
C5588RHM20/2528
C5665RHM20/50-130
C5743RHF20/2030
Mean ± SD68.7 ± 10.020/22 ± 0.228.1 ± 1.6
  • aETDRS, Early Treatment of Diabetic Retinopathy Study, visual acuity chart “R” (Precision Vision); MoCA, Montreal Cognitive Assessment, a test that rates cognitive ability on a scale from 0 to 30 (Nasreddine et al., 2005).

  • bHoehn and Yahr (1967) staging scale for symptom severity, ranging from 1 (unilateral involvement only) to 5 (confinement to bed or wheelchair).

  • cUnified Parkinson's Disease Rating Scale (Movement Disorder Society Task Force 2003). Motor Score only.

  • dMost patients were on combination drugs containing levodopa and carbidopa (e.g., Sinemet, Levocarb). Table states total daily dose in milligrams across equivalent combination drugs.